Posted 4 days ago

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov ID NCT07043400

Protocol number BGB-A317-316

Sponsor BeOne Medicines